![Praveen Tipirneni](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Praveen Tipirneni
Directeur/Membre du Conseil chez
PANACEA ACQUISITION CORP. II
Fortune : 104 397 $ au 30/06/2026
Profil
Praveen P.
Tipirneni is currently President, CEO, Secretary & Director at Caldera Therapeutics, Inc. He serves as Director at RAS, Inc. and Tectonic Operating Co., Inc. He is an Independent Director at Tectonic Therapeutic, Inc. since 2020, Panacea Acquisition Corp.
II since 2021, and Bridgebio Oncology Therapeutics, Inc. since 2024.
He is also a Non-Executive Director at Bridgebio Oncology Therapeutics, Inc. and a Venture Partner at Atlas Venture Life Science Advisors LLC.
Former roles include Chief Executive Officer & Director at Morphic Holding, Inc. (2022-2023, 2024) and Morphic Therapeutic, Inc. (2022-2024).
Independent Director at AVROBIO, Inc., Head-Strategy & Covad Communications at Sun Microsystems, Inc., Principal at Fusion MPHC Group, Inc. (Delaware), Corporate Development Manager at Deltagen, Inc., and Senior VP-Corporate Development & Global Strategy at Cubist Pharmaceuticals LLC (2012-2015).
Education includes a doctorate from McGill University, an undergraduate degree from Massachusetts Institute of Technology, and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,02 % | 09/06/2026 | 3 037 ( 0,02 % ) | 104 397 $ | 30/06/2026 |
-.--% | 16/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Praveen Tipirneni
| Sociétés | Poste | Début |
|---|---|---|
| PANACEA ACQUISITION CORP. II | Directeur/Membre du Conseil | 06/04/2021 |
RAS, Inc.
 RAS, Inc. Miscellaneous Commercial ServicesCommercial Services Provides consulting and technical field services for environmental, geotechnical, mining & water supply | Directeur/Membre du Conseil | - |
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for seed and early stage capital requirements. | Private Equity Investor | - |
Tectonic Therapeutic, Inc.
 Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies | Directeur/Membre du Conseil | - |
Anciens postes connus de Praveen Tipirneni
| Sociétés | Poste | Fin |
|---|---|---|
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Directeur Général | 01/12/2024 |
| MORC HOLD | Directeur Général | 16/08/2024 |
| MORC HOLD | Directeur Général | 01/11/2023 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01/02/2015 |
Sun Microsystems, Inc.
 Sun Microsystems, Inc. SemiconductorsElectronic Technology Develops computer and storage systems, high-speed microprocessors and software solutions for computer networking | Corporate Officer/Principal | - |
Formation de Praveen Tipirneni
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
63
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Sun Microsystems, Inc.
Sun Microsystems, Inc. SemiconductorsElectronic Technology Develops computer and storage systems, high-speed microprocessors and software solutions for computer networking | Electronic Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Fusion MPHC Group, Inc. (Delaware)
 Fusion MPHC Group, Inc. (Delaware) Specialty TelecommunicationsCommunications Provides digital communications services | Communications |
Deltagen, Inc.
 Deltagen, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug discovery tools and services to the biopharmaceutical industry | Commercial Services |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for seed and early stage capital requirements. | Finance |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
AVROBIO, Inc.
 AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
RAS, Inc.
RAS, Inc. Miscellaneous Commercial ServicesCommercial Services Provides consulting and technical field services for environmental, geotechnical, mining & water supply | Commercial Services |
Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Operates biotechnology company that transforming the discovery of novel G-protein-coupled receptors targeted therapies | Commercial Services |
Panacea Acquisition Corp. II
 Panacea Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Choisissez Zonebourse 
